Welcome to the G-FINDER survey
The G-FINDER survey tracks annual investment into R&D for new products and technologies to address priority global health challenges. This includes basic research and the development of new drugs, vaccines, diagnostics and other tools for global health priorities that disproportionately affect people in low- and middle-income countries, including neglected diseases (NDs), emerging infectious diseases (EIDs) and sexual and reproductive health (SRH) issues.
As part of the ongoing evolution and improvement of the G-FINDER project, we have adapted the scope of the survey to reflect the WHO’s new scientific framework for epidemic and pandemic research preparedness. As such, the EID scope has expanded from five to nine viral families, encompassing 16 pathogens each categorised under its respective viral family name. Specifically:
- we now track basic research and product R&D funding for Hantaan virus and highly pathogenic avian influenza A(H5N1) virus;
- we have re-introduced the tracking of dengue vaccine R&D funding (with restrictions); and
- we no longer track R&D funding for SARS-CoV-1 and emergent non-polio enteroviruses.
Please see the EID scope document for comprehensive details about these updates.
Data Tags. The ‘Tag’ feature enriches project details by allowing the addition of one or more tags, for example “paediatric formulation”, “ODA funding” or “antimicrobial resistance”. Choose from our pre-defined options or add customised tags.
The G-FINDER project has been funded by the Gates Foundation since 2007. Open Philanthropy also supports the project via core funding to Impact Global Health. For more information, please refer to the frequently asked questions.
G-FINDER reports and data portal
Our unique database of R&D investment data for global health issues can be freely accessed through the G-FINDER data portal.
Our analysis and reports based on this data can be found here.